Boston Scientific added about $300 million of quarterly revenue, but nearly $400 million of operating income. Sales rose 7.5% to $5.4 billion in the latest quarter, while operating income climbed 43.8% to $1.2 billion.
That is the headline reading of the August 3 10-Q: the medical-device maker is getting substantially more profit from each dollar of sales. Gross margin rose from 67.7% to 70.7%, and operating margin moved from 16.2% to 21.6%. The latest close was $46.73 on July 31, up 1.6% that day.
The sales growth itself was not evenly distributed. Boston Scientific says its pain portfolio and deep brain stimulation franchise led the increase, while other businesses struggled with China procurement changes and commercial disruption.
Management’s strongest growth areas were spelled out plainly:
"In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our comprehensive pain portfolio, led by our Intracept™ Intraosseous Nerve Ablation System and Nalu Peripheral Nerve Stimulation System, and our deep brain stimulation franchise." Boston Scientific, 10-Q, August 3, 2026
In plain English, the quarter’s 7.5% growth had a particular cast of characters. It was not a broad lift across every franchise.
The weaker lines were not invisible. Boston Scientific said stone products underperformed because of volume-based procurement in China, while sacral neuromodulation faced commercial disruption. Those businesses were described as relatively flat, not as another source of acceleration.
"In the second quarter and first six months of 2026, reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise." Boston Scientific, 10-Q, August 3, 2026
The margin expansion is the central financial change. Gross profit grew 12.4%, faster than sales, while operating income grew almost six times as fast as revenue. SG&A increased with higher sales, according to the company, but the filing does not assign the entire margin move to one operating cause.
There is also a small footnote to the earnings picture. For the first six months, Boston Scientific said higher sales and a discrete tax benefit recorded in the first quarter drove the increase in net income. Second-quarter net income, by contrast, was primarily driven by higher sales. Diluted EPS rose 15.1% to $0.61 for the quarter, a smaller increase than operating income.
The cash conversion numbers add a second track to the story. Cash barely changed, reaching $539 million from $534 million, while inventory rose 13.1% and accounts receivable increased 8.3%. Capital spending rose 8.1%, and free-cash-flow margin fell 1.6 percentage points. None of those movements comes with a stated cause in the 10-Q, but they give the margin expansion something concrete to keep company: profits improved faster than sales, while inventory grew faster than sales.
That is the unresolved detail in the quarter. Boston Scientific’s next quarterly report will put the current 13.1% inventory growth rate next to the next period’s revenue growth, a comparison that will show whether the balance between reported profit and cash tied up in the business has changed.
Source: Boston Scientific’s August 3, 2026 10-Q; inventory grew 13.1% year over year versus 7.5% revenue growth.